#Dermatophytic Onychomycosis Treatment Market 2026

[martynnx-blog]

Dermatophytic Onychomycosis Treatment Market Size Will Escalate Rapidly in the Near Future

Dermatophytic onychomycosis, also known as tinea unguium, is a fungal disease of toenails or fingernails that causes ring infection over nails. Trichophyton rubrum and trichophyton mentagrophytes are common strains of fungi responsible for causing dermatophytic onychomycosis. Furthermore, yeasts and non-dermatophyte molds are other agents that spread the infection. Public places such as gym, swimming pool, and others that are infected with disease causing fungal agents are major source, which cause dermatophytic onychomycosis. Moreover, continuous use of shoes for a longer duration and contact of toe nail with wet surface causes the fungal infection. Increasing incidences of the infection are evident in sportsperson, owing to continuous use of shoe, sweating at nails, and traumatic nail injuries.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2053

Market Dynamics

Major driver for growth of the dermatophytic onychomycosis treatment market is high prevalence of dermatophytic onychomycosis worldwide. According to a study published in the Journal of the European Academy of Dermatology and Venereology in 2013, the mean prevalence of dermatophytic onychomycosis in Europe and North America was 4.3% in the population-based studies and 8.9% in the hospital-based studies. According to the Centre for Disease Control and Prevention statistics in 2017, around 23 million people in the U.S. are affected by this disease each year.

Increasing geriatric population across the globe is another major factor driving growth of the market. According to the Population Prospects report by the United Nations, the number of people aged 60 years and above would reach 1.3 billion by 2025.

Increased global prevalence of dermatophytic onychomycosis is expected to propel growth of the dermatophytic onychomycosis treatment market:

Dermatophytic onychomycosis is most common nail disorder. According to a report in the Journal of Cutaneous Medicine and Surgery, 2017, onychomycosis accounts for 50% of all nail diseases and prevalence of onychomycosis was estimated to be 5.5% with margin of error of + 3% worldwide. Prophylactic use of topical antifungal agent is expected to aid in effective treatment of dermatophytic onychomycosis, which in turn is major factor contributing to the market growth.

However, several factors deter growth for the dermatophytic onychomycosis treatment market. For instance, treatment of dermatophytic onychomycosis on an average lasts for 5-6 months and with such long term course, patient’s compliance is a critical problem with dose fatigue and adverse effects on body parts such as liver, kidney, and heart (hepatic, renal impairment).

Key players operating in the dermatophytic onychomycosis treatment market include, Bausch Health Companies, Galderma S.A., Celtic Pharma, Anacor pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Pfizer Inc.,  GlaxoSmithKline, Topica Pharmaceuticals, Inc., Moberg Pharma AB, Bayer AG, Dr. Reddy’s Laboratories Ltd, Allergen, Inc.,  Cipla Ltd, Medimetriks Pharmaceuticals Inc., Sanofi S.A., NovaBiotics Inc., and  Merz Pharma.

[cool-akashy-maximize]

Trichophyton mentagrophytes and Trichophyton rubrum are mutual strains of fungi responsible for causing dermatophytic onychomycosis.

[mysteriouslysizzlingobserva-blog]

Global Dermatophytic Onychomycosis Treatment Market was value US$ 2.6Bn in 2017 and is expected to reach US$ 7.1Bn by 2026 at a CAGR of 13.38%. Dermatophytic onychomycosis also called as tinea unguium, is a fungal disease of toenails or fingernails that causes ring infection over nails. Trichophyton mentagrophytes and Trichophyton rubrum are mutual strains of fungi responsible for causing dermatophytic onychomycosis.

[rajputdishank20-blog]

Global Dermatophytic Onychomycosis Treatment Market by Types, Routes of Administration, End-users, and Regions – Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2020 – 2026

The global dermatophytic onychomycosis treatment market was valued at USD 2.6 billion in 2019 and is expected to reach USD 7 billion by 2026,    expanding at a CAGR of around 13% during the forecast period, 2020 – 2026. Consistently growing prevalence of onychomycosis infections around the world along with the advancements of novel medications available for commercial treatment of onychomycosis infections are the major factors driving the market growth. Additionally, the increasing geriatric population who are susceptible of getting infections with increasing treatment rate are some other factors driving the growth of the dermatophytic onychomycosis treatment market during the forecast period.

Tinea unguium also called as dermatophytic onychomycosis, is a fungal disease of fingernails or toenails that causes ring infection over nails. Mutual stains of fungi trichophyton rubrum and trichophyton mentagrophytes are responsible for causing dermatophytic onychomycosis. With the growing incidence of chronic diseases, such as diabetes, psoriasis, and peripheral vascular diseases the prevalence of dermatophytic onychomycosis is increasing. Many such secondary factors are expected to influence the growth of dermatophytic onychomycosis treatment market.

Market Trends, Drivers, Restraints, and Opportunities:

Growing prevalence of dermatophytic onychomycosis is the major factor influencing the growth of the market.

Rising geriatric population is expected to fuel the growth of the market during the forecast period.

Technological advancements in medical treatments and increasing competitive landscape are driving the growth of the market.

Increased government spending and increasing activities in R&D by companies will create new opportunities in terms of revenue which will in turn lead to market growth.

Risk in medication errors by a medical professional may act as restrain to the growth of the market.

Use of antifungal drugs used in the treatment of dermatophytic onychomycosis have certain side effects which may hamper the market growth.

High cost of infrastructure and lack of availability of skilled workforce will act as a restrain for this market during the forecast period.

Read More: https://dataintelo.com/report/dermatophytic-onychomycosis-treatment-market/

[apurvafmi-blog]

According to the latest report published by Persistence Market Research titled “Dermatophytic Onychomycosis Therapeutics Market: Global Industry Analysis 2013–2017 and Forecast 2018–2026,” the dermatophytic onychomycosis therapeutics market in terms of value is expected to grow at a CAGR of 7.6% during the forecast period.

Dermatophytic onychomycosis also known as tinea guinea can have certain negative effects on patients, such as pain, and can potentially undermine their work and social lives. Moreover, the infection might spread to surrounding skin. The condition isn’t considered life-threatening,  but may result in physical and occupational limitations, because of which more and more number of people are opting for the treatment of their infected, thick, and cracked nails.  This, in turn, is driving growth of the market for dermatophytic onychomycosis therapeutics.

The global dermatophytic onychomycosis therapeutics market based on product type has been segmented into tablets and nail paints, which is again sub-segmented into prescription (Rx) and over-the-counter. The nail paint segment is expected to contribute maximum share in the global dermatophytic onychomycosis therapeutics market and expand at a CAGR of 8.1% during the forecast period. Based on treatment type, the global dermatophytic onychomycosis therapeutics market has been segmented into topical and oral. The topical is projected to be the dominant segment throughout the forecast period, accounting for around 70% share of the global dermatophytic onychomycosis therapeutics market by 2026.

Based on end users, the global dermatophytic onychomycosis therapeutics market has been segmented into hospitals, clinics, independent pharmacies, mail order pharmacies and drug stores. The drug stores & independent pharmacies segments are estimated to be the large segments, which collectively accounted approximately 54% share of the global dermatophytic onychomycosis therapeutics market in 2017. The independent pharmacies segment is expected to register a high CAGR growth during the forecast period. The drug stores was the second most attractive segment in the global dermatophytic onychomycosis therapeutics market in 2017.

Request Sample Report@ https://www.persistencemarketresearch.com/samples/5840

The growth of the market is primarily driven by factors such as increase in the prevalence of fungal toe nail infections in the U.S. and Canada, and rising per capita healthcare expenditure across the globe. Dermatophytic onychomycosis is common in the elderly, with prevalence rates as high as 20% in those over 60 years of age and 30% in those over 70. Thus increasing geriatric population is the most important factor that is expected to drive growth of the dermatophytic onychomycosis therapeutics market over the forecast period. Easy application of nail paints is also expected to drive the demand for dermatophytic onychomycosis therapeutics. Another factor fueling the growth of dermatophytic onychomycosis therapeutics market is the growing preference of dermatophytic onychomycosis therapeutics by podiatrists and dermatologists.

Rise in diagnosis of the nail infection has raised awareness regarding the fungal infection of nails and dermatophytic onychomycosis therapeutics. Besides, increasing awareness regarding dermatophytic onychomycosis therapeutics amongst podiatrists and dermatologists has led to a rise in demand for effective medications. However, adverse effects such as headache, dizziness, nausea, stomach ache, etc., associated with antifungal drugs have made people more skeptical about practicing a systemic therapy for nails. Moreover, the topical agents also causes rash and itchiness in the surrounding skin. These side effects are hampering the acceptance of dermatophytic onychomycosis therapeutics for the treatment of moderate to severe dermatophytic onychomycosis associated with anti-fungal therapeutics. Another factor impeding the growth of dermatophytic onychomycosis therapeutics is lack of awareness regarding dermatophytic onychomycosis therapeutics and dermatophytic onychomycosis itself. There is a general lack of awareness regarding the disease, its possible causes, symptoms etc. People in some African, European, Gulf, and Asian countries are still ignorant about their diseased nails. There is a general perception among patients that the thickened nail would get cured by itself after sometime. Thus, lack of awareness is also a major factor hindering growth of the onychomycosis therapeutics market currently.

Geographically, the global dermatophytic onychomycosis therapeutics market is segmented into five major regions, namely North America, Latin America, Europe, Asia Pacific, and Middle East & Africa (MEA). North America was the dominant regional market for dermatophytic onychomycosis therapeutics and is expected to follow the same trend over the forecast period. The Europe market for dermatophytic onychomycosis therapeutics is expected to account for second large share followed by Asia Pacific. North America and Europe collectively are expected to account for over 60% share of the global dermatophytic onychomycosis therapeutics market over the forecast period. MEA and Latin America are expected to be the fast-growing regions in the global dermatophytic onychomycosis therapeutics market due to growing healthcare efforts.

Request TOC@ https://www.persistencemarketresearch.com/methodology/5840

Dermatophytic Onychomycosis Therapeutics Market: Key Players

Examples of some of the key players operating in the global dermatophytic onychomycosis therapeutics market are Valeant Pharmaceuticals Inc, Galderma S.A., Novartis AG, Pfizer Inc, Moberg Pharma AB, Johnson & Johnson Services Inc, Bayer AG, Dr. Reddy’s Laboratories Ltd, Cipla Ltd, and Medimetriks Pharmaceuticals Inc.

[martynnx-blog]

Dermatophytic Onychomycosis Treatment Market Growth Analysis, Share, Demand by Regions, Types and Analysis of Key Players- Research Forecasts to 2026

Dermatophytic onychomycosis, also known as tinea unguium, is a fungal disease of toenails or fingernails that causes ring infection over nails. Trichophyton rubrum and trichophyton mentagrophytes are common strains of fungi responsible for causing dermatophytic onychomycosis. Furthermore, yeasts and non-dermatophyte molds are other agents that spread the infection. Public places such as gym, swimming pool, and others that are infected with disease causing fungal agents are major source, which cause dermatophytic onychomycosis. Moreover, continuous use of shoes for a longer duration and contact of toe nail with wet surface causes the fungal infection. Increasing incidences of the infection are evident in sportsperson, owing to continuous use of shoe, sweating at nails, and traumatic nail injuries.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2053

Market Dynamics

Major driver for growth of the dermatophytic onychomycosis treatment market is high prevalence of dermatophytic onychomycosis worldwide. According to a study published in the Journal of the European Academy of Dermatology and Venereology in 2013, the mean prevalence of dermatophytic onychomycosis in Europe and North America was 4.3% in the population-based studies and 8.9% in the hospital-based studies. According to the Centre for Disease Control and Prevention statistics in 2017, around 23 million people in the U.S. are affected by this disease each year.

Increasing geriatric population across the globe is another major factor driving growth of the market. According to the Population Prospects report by the United Nations, the number of people aged 60 years and above would reach 1.3 billion by 2025.

Increased global prevalence of dermatophytic onychomycosis is expected to propel growth of the dermatophytic onychomycosis treatment market:

Dermatophytic onychomycosis is most common nail disorder. According to a report in the Journal of Cutaneous Medicine and Surgery, 2017, onychomycosis accounts for 50% of all nail diseases and prevalence of onychomycosis was estimated to be 5.5% with margin of error of + 3% worldwide. Prophylactic use of topical antifungal agent is expected to aid in effective treatment of dermatophytic onychomycosis, which in turn is major factor contributing to the market growth.

Key players operating in the dermatophytic onychomycosis treatment market include, Bausch Health Companies, Galderma S.A., Celtic Pharma, Anacor pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Pfizer Inc.,  GlaxoSmithKline, Topica Pharmaceuticals, Inc., Moberg Pharma AB, Bayer AG, Dr. Reddy’s Laboratories Ltd, Allergen, Inc.,  Cipla Ltd, Medimetriks Pharmaceuticals Inc., Sanofi S.A., NovaBiotics Inc., and  Merz Pharma.

Browse Complete Report For More Information @ https://www.coherentmarketinsights.com/market-insight/dermatophytic-onychomycosis-treatment-market-2053